Cookies on VetMed Resource

Like most websites we use cookies. This is to ensure that we give you the best experience possible.

 

Continuing to use www.cabi.org  means you agree to our use of cookies. If you would like to, you can learn more about the cookies we use.

VetMed Resource

Veterinary information to support practice, based on evidence and continuing education

Sign up to receive our Veterinary & Animal Sciences e-newsletter, book alerts and offers direct to your inbox.

Results per page:

Search results

Abstract

Despite numerous published studies describing adjuvant chemotherapy for canine appendicular osteosarcoma, there is no consensus as to the optimal chemotherapy protocol. The purpose of this study was to determine whether either of two protocols would be associated with longer disease-free interval...

Author(s)
Skorupski, K. A.; Uhl, J. M.; Szivek, A.; Frazier, S. D. A.; Rebhun, R. B.; Rodriguez, C. O., Jr.
Publisher
Wiley-Blackwell, Oxford, UK
Citation
Veterinary and Comparative Oncology, 2016, 14, 1, pp 81-87
Abstract

Osteosarcoma (OSA) is the most common malignant bone cancer in children and dogs. The therapeutic protocols adopted for dogs and humans are very similar, involving surgical options such as amputation. Besides surgical options, radiotherapy and chemotherapy also are adopted. However, hematologic,...

Author(s)
Rici, R. E. G.; Will, S. E. A. L.; Luna, A. C. L.; Melo, L. F.; Santos, A. C.; Rodrigues, R. F.; Leandro, R. M.; Maria, D. A.
Publisher
Wiley, Oxford, UK
Citation
Veterinary and Comparative Oncology, 2018, 16, 4, pp 478-488
Abstract

5-Fluorouracil (5-FU) is used in combination chemotherapy protocols for human head and neck cancer and other epithelial neoplasms. However, a paucity of literature describing use of this drug in veterinary oncology exists, likely due to previous reports of fatal neurotoxicity in both dogs and cats, ...

Author(s)
Menard, K.; Flesner, B. K.; Glahn, A.; Boudreaux, B.; Bryan, J. N.
Publisher
Wiley, Oxford, UK
Citation
Veterinary and Comparative Oncology, 2018, 16, 4, pp 590-595
Abstract

OBJECTIVE: To evaluate adverse events and outcomes in dogs with appendicular osteosarcoma treated with limb amputation followed by a single SC infusion of carboplatin. ANIMALS: 45 client-owned dogs with appendicular osteosarcoma treated with limb amputation and SC infusion of carboplatin between...

Author(s)
Santamaria, A. C.; Simcock, J. O.; Kuntz, C. A.
Publisher
American Veterinary Medical Association, Schaumburg, USA
Citation
Journal of the American Veterinary Medical Association, 2019, 255, 3, pp 345-351
Abstract

Background: Oclacitinib is an orally bioavailable Janus Kinase (JAK) inhibitor approved for the treatment of canine atopic dermatitis. Aberrant JAK/Signal Transducer and Activator of Transcription (STAT) signaling within hematologic and solid tumors has been implicated as a driver of tumor growth...

Author(s)
Barrett, L. E.; Gardner, H. L.; Barber, L. G.; Sadowski, A.; London, C. A.
Publisher
BioMed Central Ltd, London, UK
Citation
BMC Veterinary Research, 2019, 15, 291, pp (13 August 2019)
Abstract

Osteosarcoma is the most common paediatric primary bone malignancy. The major cause of death in osteosarcoma is drug-resistant pulmonary metastasis. Previous studies have shown that thioredoxin reductase 2 is a driver of metastasis in osteosarcoma and can be inhibited by auranofin (AF). Moreover,...

Author(s)
Endo-Munoz, L.; Bennett, T. C.; Topkas, E.; Wu, S. Y.; Thamm, D. H.; Brockley, L.; Cooper, M.; Sommerville, S.; Thomson, M.; O'Connell, K.; Lane, A.; Bird, G.; Peaston, A.; Matigian, N.; Straw, R. C.; Saunders, N. A.
Publisher
Wiley, Oxford, UK
Citation
Veterinary and Comparative Oncology, 2020, 18, 2, pp 206-213
Abstract

Osteosarcoma remains the most common primary bone tumour in dogs with half of affected dogs unable to survive 1 year beyond diagnosis. New therapeutic options are needed to improve outcomes for this disease. Recent investigations into potential therapeutic targets have focused on cell surface...

Author(s)
Alegre, F.; Ormonde, A. R.; Godinez, D. R.; Illendula, A.; Bushweller, J. H.; Wittenburg, L. A.
Publisher
Wiley, Oxford, UK
Citation
Veterinary and Comparative Oncology, 2020, 18, 1, pp 52-63
Abstract

Osteosarcoma, a common malignancy in large dog breeds, typically metastasises from long bones to lungs and is usually fatal within 1 to 2 years of diagnosis. Better therapies are needed for canine patients and their human counterparts, a third of whom die within 5 years of diagnosis. We compared...

Author(s)
Patatsos, K.; Shekhar, T. M.; Hawkins, C. J.
Publisher
Wiley, Oxford, UK
Citation
Veterinary and Comparative Oncology, 2018, 16, 4, pp 544-553
Abstract

Limb-sparing for distal radial osteosarcoma has a high rate of complications. Using personalized three-dimensional (3D)-printed implants might improve outcome. The goals of this study were to optimize use of patient-specific, 3D-printed endoprostheses for limb-sparing in dogs in the clinical...

Author(s)
Séguin, B.; Pinard, C.; Lussier, B.; Williams, D.; Griffin, L.; Podell, B.; Mejia, S.; Timercan, A.; Petit, Y.; Brailovski, V.
Publisher
Wiley, Oxford, UK
Citation
Veterinary and Comparative Oncology, 2020, 18, 1, pp 92-104
Abstract

There is no widely accepted standard of care for canine anal sac apocrine gland adenocarcinoma (ASAGAC). Surgery alone is inadequate in many cases, but the benefit of adjuvant chemotherapy is not well established. The primary objective of this retrospective study was to evaluate the role of ...

Author(s)
Wouda, R. M.; Borrego, J.; Keuler, N. S.; Stein, T.
Publisher
Wiley-Blackwell, Oxford, UK
Citation
Veterinary and Comparative Oncology, 2016, 14, 1, pp 67-80

Refine Results

Sort Order
Author
Geographical Location
Item Type
Language
Organisms
Subject Topics